Bet you were also shorting Netflix.
Shorting, you are paying points to borrow the stock, and you have unlimited risk. Going long, you are often paid to hold the stock (dividend), and your risk is limited to your investment.
Shorting, you can get hit by margin calls, when you by a stock long(not on margin) there is never a risk of a margin call. Can't "buy" a short position, unless you buy Puts, and then they expire -- so you are definitely trying to time the market.
Shorting, you will likely be paying short term capital gains... Longs who invest generally pay long term cap gains. I have held SNDK for years and have a basis of around $14. Lots of ups and downs, but staying long has proven the best decision.
Shorting just feels super negative to me as well. Making money exploiting the pain of others. I'd rather bet on things I believe in. JMHO. Best to all...
And yet we all want unlimited medical coverage for less than $3,000./year. I don't get how the insurance industry works if they cover everything... a 20k procedure is approx. 4-6 years of premiums for average individual insurance. Who's paying for that?
Who would have thought that FDA approval was already baked into the price. So, it appears that at $2. valuation, this stock was 40% overvalued by the market. I bought several years ago, in the low $2 range and have cost averaged down over the years. However this stock is approaching its multi year low. There have to be people who bought into the Hype early, in the $40-$60 range... and a lot more who bought in in the $4-$10 range. Everybody who has bought in (and held) has lost. As the ~8 year low is, I believe $.96, the most a long term investor (not trader), could be up on this stock is a little over 25%. That is pitiful, given the performance of other Biotech companies.
So please don't encourage people who don't understand the history of this stock -- and who may not have strong stomachs (npi) -- to invest in this stock. Lack of investor commitment and manipulation of investors by traders is what destroys value more than anything.
Stop the Hype!
Been in this co. for 2 years and it has been a world of pain. One month ago buy_sell_sell_buy callet this "a solid company." It has now dropped 30% in a month. Ugggg-llyyyy. Anyone have any insights?
This is a serious question. I got into this stock... and out with a small profit because I can't find the timeline for release of pharmaceuticals. I know some are approved for sale in Europe, but analysts who rate this a buy/strong buy project declining revenues. I simply want information. Not bashing, but I have been burned too many times. You should want this info as well. Buying on the Marijuana connection, or momentum, or even analysts recommendations is not enough. Look at CANN. It shot up to $64. but today trades at $1.11. I'm not saying GWPH is the same, but if people in CANN asked questions and were told ignore, they may have lost all their money.
Any appreciate info from any legitimate investor out there.
Someone please explain the price of this to me. Average analyst rates this a buy/strong buy... yet has the company's revenues dropping almost 20% next year. Meanwhile it trades a almost 30x next years revs. I understand the idea of speculative, but where's the beef?
Message boards would be great if they were a place for insightful and honest discussion. Unfortunately, 90+ % of the people on these boards have an agenda (pump or dump) that drives their posts and "insights." I'm holding. This is an interesting sector and it is easy to buy high and sell low. If you have a reason for not believing in the prospects of XONE, then I would suggest selling, taking the write off, and reallocating the proceeds to another 3D printer company you like better... say SSYS or HPQ (although HP has a lot of other stuff that will limit its growth prospects, albeit make it less risky). Luck to all.
"Those smarter and more informed than me may know the answer"
And I doubt you will find them... or be able to identify them, on this thread/message board. Message boards would be great if they were a place for insightful and honest discussion. Unfortunately, 90+ % of the people on these boards have an agenda (pump or dump) that drives their posts and "insights." I'm holding. This is an interesting sector and it is easy to buy high and sell low. If you have a reason for not believing in the prospects of XONE, then I would suggest selling, taking the write off, and reallocating the proceeds to another 3D printer company you like better... say SSYS or HPQ (although HP has a lot of other stuff that will limit its growth prospects, albeit make it less risky). Luck to all.
Hard to have a short squeeze with the float tripling. I have no position in this stock, but you have to look at the valuation relative to peers...
Actually, NUAN is a reason I am concerned about CRUS. NUAN had extremely proprietary, best of class technology. Unlike CRUS, NUAN has had virtually no competition. Now APPL is raiding NUAN for its engineers and creating their own speech recognition technology. APPL could easily do the same to CRUS, or partner with another chip company. That is why CRUS sells at a discount. Until it happens to you, you don't see it coming. APPL has become a fairly predatory company.
Not really, because then they are paying R&D and overhead. And then they are supplying their competitors as well. And then they are pretty much locked into a technology... even if something better comes along. CRUS is priced at a discount because it is so dependent on APPL.
Until the lock-up ends and then shares will flood the market. This is a good company, but too richly valued. They have to have 5+ years of 20+% growth to justify this valuation (already has a larger market cap than Nikon). I would be scared to touch this, until it pulls back a lot.
Apologies.... want to rename this ARE APPLE SUPPLIERS DOOMED? Remember I'm just in a different lifeboat than you are if you own CRUS (I own NUAN).
Been following this stock for a couple of years (as well as a couple of other Apple suppliers) and the problem is that they don't control their own business... Apple does. Companies like CRUS and GTAT(Q) operate at Apple's whim. Someone could buy it... Apple could buy it, but why? Not owning gives Apple the flexibility to move if better technology appears elsewhere, as well as the leverage to squeeze margins for CRUS. This really sucks for CRUS and other Apple suppliers, but it seems to be reality. These companies have no protection. Apple's behavior seems pretty shameful. They seem to have become the Mafia of the tech world -- you do business their way or you get whacked. NUAN (Nuance), which I do own(sadly), is another example. Apple has the power to clone the technologies they do like, and leave the creators in the dust. Apple accuses Samsumg of this, but Samsung seems way less nefarious than Apple, especially in their dealings with suppliers. Samsung is dealing in a commodity... Apple is all about a marketing image. When they are on equal tech terms, Samsung wins. What I am starting to wonder about as an investor is how you can win in this space. Perhaps it is better to own comsumer staples stocks. Perhaps selling all my tech and buying P&G, Kellogs, and maybe a big pharma co. Any thoughts out there from embattled CRUS shareholders?
Here's (part of) what the Forbes article said:
"And if you’re a big company like LinkedIn, with a big market capitalization and no debt, the convertible will cost you next to nothing—maybe nothing—in cash interest. Meanwhile, LinkedIn won’t be issuing stock, according to the preliminary terms, unless the stock gets at least 40% above its current perch. Call it 330-ish.
And what’s more, LinkedIn is actually going to cut the kind of side deal that’s become almost customary in big convertible issues. It will use a portion of the deal to buy back stock—or, if you want to be technical, to enter an option trade that has the joint economic effects of buying back some stock now and raising the effective conversion price of the bond to something more like 400. This “anti-dilution” step comes at a cost, but trust me: it’s a very reasonable cost. This is very cheap and very smart financing by a very smart company."